L. Nathan Tumey, Associate Professor at Binghamton University, shared a post on LinkedIn:
“Immune-stimulating antibody conjugates (ISACs) are gaining traction! I’m excited to share the full story of our exploration of the role of FcγR’s in the design of TLR7-based ISACs. Historically, ISACs have relied on FcγR’s for uptake into tumor-associated myeloid cells. However, we explain how the combination of a cell permeable payload, a cleavable linker, and a Fc-silenced mAb can lead to robust anti-tumor activity with improved safety in murine models as compared to traditional ISAC designs.
A special shout-out to Samantha Benjamin and Siteng Fang for leading the efforts for this publication (this work formed key chapters for both of their dissertations!). Key contributions were also made by Lina Wu, Mohammad Asikur Rahman, Kayla Elder, Victor Ojo, Tao Zhang, and Tracy Brooks. Keep an eye open for a rapid follow-on publication that we expect to publish in the coming weeks that will expand upon this work!
Interested in licensing or working with us on these ISAC designs? Just reach out.”
Title: Dissecting the Efficacy and Immunogenicity of TLR7 Agonist–Antibody Conjugates through the Lens of Fc Effector Function, Conjugation Strategies, and Linker Cleavability
Authors: Siteng Fang, Samantha R. Benjamin, Lina Wu, Mohammad Asikur Rahman, Kayla K. Elder, Victor T. Ojo, Tao Zhang, Tracy A. Brooks, L. Nathan Tumey
Read the Full Article.
More posts on OncoDaily.